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Division of Nephrology & Hypertension, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, United StatesHyperkalemia is usually seen in patientswith chronic kidney disease
(CKD) when renal excretion of potassium (K+) is reduced below the
level of intake. Normal K+ intake does not cause hyperkalemia despite
a progressive fall in glomerular ﬁltration rate (GFR) until a critically
low level, usually less than 25 mL/min, is achieved (Batlle et al., 1981).
This is due to adaptive mechanisms that permit the excretion of a nor-
mal daily K+ load despite reduced GFR. Part of this adaptation involves
the release of aldosterone from the adrenal glands. Aldosterone acts on
the kidney promoting K+ secretion. When the release of aldosterone is
reduced — as in patients with idiopathic hypoaldosteronism or during
the administration of renin angiotensin system (RAS) blockers or aldo-
sterone antagonists — hyperkalemia often develops. In fact, the thera-
peutic use of these agents in patients with CKD, diabetic nephropathy
or congestive heart failure is often limited by the development of
hyperkalemia as a potentially dangerous side-effect. Since hyperkalemia
usually develops as a result of reduced renal K+ secretion, the question
that arises is: can we rely on ampliﬁcation of colonic K+ excretion as a
route of external disposal?
There are a number of similarities and differences between colonic
and kidney K+ secretion. Two types of apical membrane K+ channels
that permit K+ secretion have been identiﬁed. The renal outer medul-
lary K+ channel (ROMK) is a low conductance K+ channel which is
present in the kidney (Wade et al., 2011; Frindt and Palmer, 2010).
The large conductance K+ channel (BK), is present in both principal
and intercalated cells in the kidney (Najjar et al., 2005) and also in the
colon (Sausbier et al., 2006). Aldosterone stimulates the Epithelial Sodi-
um Channel (ENaC), causing a negative transepithelial potential and in-
creasing the driving force for K+ secretion via the ROMK channel. In the
colon, the BK channel is the channel present in the apical site where it
mediates K+ secretion. There is also active transport of K+ across
basolateral membrane through Na–K-ATPase and Na–K-2Cl co-
transport into cells. A negative potential difference across the colonic lu-
minal membrane and the high intracellular K+ also facilitate secretion
of K+ through the BK channel. K+ absorption occurs in the distal
colon as a result of active translocation of K+ via a colonic H–K-ATPase.
The colon normally accounts for a small portion, about 5%, of total
K+ elimination, whereas the kidneys account for the remaining 95%.
The colon, however, can become a signiﬁcant site of K+ excretion⁎ Corresponding author.
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changes, colonic adaptive changes take place including: an increase
in Na–K-ATPase activity, a rise in basal K+ secretion and an increase
in transmural potential difference. These changes are mediated by
aldosterone-dependent and independent mechanisms. An increase in
K+ secretory capacity of rectal mucosa has been demonstrated in pa-
tients with advanced CKD (Sandle et al., 1986). While importantly,
this natural adaptive increase in colonic K+ secretion is not enough to
prevent hyperkalemia. This K+ secretory capacity, however, renders
the colon a potential target for therapies aimed to treat and prevent
hyperkalemia.
Two new colonic K+ binders have shown efﬁcacy in lowering plas-
ma K+ in recent clinical trials, thereby creating great expectations
(Kosiborod et al., 2014; Packham et al., 2015; Bakris et al., 2015; Weir
et al., 2015). Howdo these intestinal K+binderswork?Under basal con-
ditions, theK+absorptive process predominates in colon over the secre-
tory process. Since in CKD the increased K+ secretion in the colon is
already an adaptive mechanism, limiting the amount of K+ available
for reabsorption in the distal colon is an effective way to eliminate
this cation in the stool. K+ binders make K+ unavailable for absorption
by trapping it within the binder molecule, which is then excreted
with the feces. Carboxylic and sulfonic cation exchange resins have
long been used to bind K+ in the gastrointestinal (GI) tract. Kayexalate
(sodiumpolystyrene sulphonate) is inwide use tomanagehyperkalemia
but usually is given acutely or short-term because of concerns with its
side effects. To prevent constipation and increase Kayexalate's efﬁcacy,
sorbitol, an osmotic laxative, is often co-administered. The mixture
with sorbitol at high concentrations, however, carries a risk of colonic ne-
crosis and other serious GI adverse events.
Zirconium Silicate (ZS) and Patiromer are two new K+ binders
being introduced to manage hyperkalemia that do not require co-
administration of sorbitol and promise to be more effective than
Kayaxalate. Due to its pore size and composition, ZS can mimic
the high selectivity of physiological K+ channels. This explains the
N25-fold selectivity of ZS for K+ over divalent cations such as Ca2+ or
Mg2+. ZS can effectively trap K+, starting slowly from very low gastric
pH, while rapid and sustained K+ uptake occurs as the pH increases
in the colon where K+ concentrations are higher. Patiromer has a
novel chemical composition that promotes ionization of polymeric
K+-binding moiety under pH conditions present along the GI tract
using Ca2+ in cation exchange (Bakris et al., 2015; Weir et al., 2015).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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throughout the GI tract but preferentially binds K+ in the colon with a
net effect of facilitating its fecal excretion (Weir et al., 2015). While the
rationale for these new binders is sound, additional information on
mechanism of action and impact on colon K+ transporters as well as
evaluation of possible interactionswith other drugswould bewelcomed.
In short and long-term studies involving patients on concomitant
RAS therapy, both ZS and Patiromer have been found effective in lower-
ing plasma K+ as compared to placebo. Neither compound, however,
has been compared to Kayaxalate in terms of efﬁcacy. By facilitating
fecal K+ excretion, these new binders are likely to open new venues
for the treatment and prevention of hyperkalemia in high-risk patients,
such as those in need of long term therapy with RAS-blockers and aldo-
sterone antagonists for cardiovascular and kidney disease. With the
new binders these therapies may be extended to patients, in whom
concerns with hyperkalemia have precluded their use. We may be en-
tering a new age: the colonic age of the treatment and prevention of
hyperkalemia. This may bring clinical beneﬁts for patients who other-
wise could not tolerate RAS blockers and/or aldosterone antagonists
and perhaps ease the strict K+ dietary restrictions that patients with
end stage renal disease need to endure.
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